Central nervous system-acting drugs influencing hypothalamic-pituitary- adrenal axis function

Endocrine Development

Volumn 17, Issue , 2009, Pages 108-120

  Locatelli, Vittorio ^a   Bresciani, Elena ^a   Tamiazzo, Laura ^a   Torsello, Antonio ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; BETAMETHASONE; CARBACHOL; CENTRAL NERVOUS SYSTEM AGENTS; CITALOPRAM; CYPROHEPTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; FLUOXETINE; FLUTICASONE; GLUCOCORTICOID; HEXAMETHONIUM; ITRACONAZOLE; MEGESTROL ACETATE; METHYSERGIDE; MIRTAZAPINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; PHENTOLAMINE; PHENYLEPHRINE; PHYSOSTIGMINE; PROPRANOLOL; PROTEINASE INHIBITOR; SALMETEROL; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

ADRENAL INSUFFICIENCY; ASTHMA; AUTOIMMUNE DISEASE; BREAST CANCER; CACHEXIA; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; CORTICOTROPIN RELEASE; CUSHING DISEASE; CUSHING SYNDROME; CUSHINGOID SYNDROME; CYTOKINE RELEASE; DEPRESSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATION; MOON FACE; NEGATIVE FEEDBACK; NEOPLASM; NONHUMAN; OBESITY; PANIC; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; UTERUS CANCER; WEIGHT GAIN;

ACETYLCHOLINE; CATECHOLAMINES; CENTRAL NERVOUS SYSTEM AGENTS; GAMMA-AMINOBUTYRIC ACID; GLUCOCORTICOIDS; HISTAMINE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEUROPEPTIDES; PITUITARY-ADRENAL SYSTEM; SEROTONIN; SEROTONIN AGENTS;

EID: 84925844980     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000262533     Document Type: Review

References (57)

1. Antoni FA: Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr Rev 1986;7:351.
2. Gaillard RC, Al-Damluji S: Stress and the pituitaryadrenal axis. Baillieres Clin Endocrinol Metab 1987; 1:319.
3. Dunn AJ: Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 2006;6:52.
4. Calogero AE: Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron. Ann NY Acad Sci 1995;771:31.
5. Givalois L, Li S, Pelletier G: Central nitric oxide regulation of the hypothalamic-pituitary-adrenocortical axis in adult male rats. Brain Res Mol Brain Res 2002;102:1.
6. Jacobson L, Sapolsky R: The role of the hippocampus in feedback regulation of the hypothalamicpituitary- adrenocortical axis. Endocr Rev 1991;12: 118.
7. Reul JM, de Kloet ER: Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505.
8. Ferrini M, Lima A, De Nicola AF: Estradiol abolishes autologous downregulation of glucocorticoid receptors in brain. Life Sci 1995;57:2403.
9. Weiser MJ, Handa RJ: Estrogen impairs glucocorticoid dependent negative feedback on the hypothalamic- pituitary-adrenal axis via estrogen receptor alpha within the hypothalamus. Neuroscience 2009; 159:883.
10. Lachize S, Apostolakis EM, van der Laan S, Tijssen AM, Xu J, de Kloet ER, Meijer OC: Steroid receptor coactivator-1 is necessary for regulation of corticotropin- releasing hormone by chronic stress and glucocorticoids. Proc Natl Acad Sci USA 2009;106: 8038-8042.
11. Weiner RI, Ganong WF: Role of brain monoamines and histamine in regulation of anterior pituitary secretion. Physiol Rev 1978;58:905.
12. Labrie F, Gagné B, Lefèvre G, Meunier H: CRF stimulates adenylate cyclase activity in the intermediate lobe of the pituitary gland. Mol Cell Endocrinol 1983;30:347.
13. Plotsky PM, Bruhn TO, Vale W: Hypophysiotropic regulation of adrenocorticotropin secretion in response to insulin-induced hypoglycemia. Endocrinology 1985;117:323.
14. Fuller RW: The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 1992;13:250.
15. Cavagnini F, Panerai AE, Valentini F, Bulgheroni P, Peracchi M, Pinto M: Inhibition of ACTH response to oral and intravenous metyrapone by antiserotoninergic treatment in man. J Clin Endocrinol Metab 1975;41:143.
16. Palacios JM, Waeber C, Hoyer D, Mengod G: Distribution of serotonin receptors. Ann NY Acad Sci 1990;600:36.
17. Heisler LK, Pronchuk N, Nonogaki K, Zhou L, Raber J, Tung L, Yeo GS, ORahilly S, Colmers WF, Elmquist JK, Tecott LH: Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J Neurosci 2007;27:6956.
18. Calogero AE, Gallucci WT, Bernardini R, Saoutis C, Gold PW, Chrousos GP: Effect of cholinergic agonists and antagonists on rat hypothalamic corticotropin- releasing hormone secretion in vitro. Neuroendocrinology 1988;47:303.
19. Rhodes ME, Billings TE, Czambel RK, Rubin RT: Pituitary-adrenal responses to cholinergic stimulation and acute mild stress are differentially elevated in male and female M[2] muscarinic receptor knockout mice. J Neuroendocrinol 2005;17:817.
20. Rubin RT, Sekula LK, OToole S, Rhodes ME, Czambel RK: Pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration in normal women and men. Neuropsychopharmacology 1999;20:434.
21. Miklós IH, Kovács KJ: GABAergic innervation of corticotropin-releasing hormone [CRH]-secreting parvocellular neurons and its plasticity as demonstrated by quantitative immunoelectron microscopy. Neuroscience 2002;113:581.
22. Cullinan WE, Ziegler DR, Herman JP: Functional role of local GABAergic influences on the HPA axis. Brain Struct Funct 2008;213:63.
23. Petraglia F, Bakalakis S, Facchinetti F, Volpe A, Muller EE, Genazzani AR: Effects of sodium valproate and diazepam on beta-endorphin, beta-lipotropin and cortisol secretion induced by hypoglycemic stress in humans. Neuroendocrinology 1986;44:320.
24. Kjaer A, Knigge U, Madsen EL, Se-Jensen P, Bach FW, Warberg J: Insulin/hypoglycemia-induced adrenocorticotropin and beta-endorphin release: involvement of hypothalamic histaminergic neurons. Endocrinology 1993;132:2213.
25. Allolio B, Deuss U, Kaulen D, Winkelmann W: Effect of meclastine, a selective H1 receptor antagonist, upon ACTH release. Clin Endocrinol [Oxf] 1983;19:239.
26. Sumitomo T, Suda T, Nakano Y, Tozawa F, Yamada M, Demura H: Angiotensin II increases the corticotropin- releasing factor messenger ribonucleic acid level in the rat hypothalamus. Endocrinology 1991;128:2248.
27. Nussdorfer GG, Malendowicz LK: Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 1998; 19:1443.
28. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS: Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250.
29. Giordano R, Pellegrino M, Picu A, Bonelli L, Balbo M, Berardelli R, Lanfranco F, Ghigo E, Arvat E: Neuroregulation of the hypothalamus- pituitaryadrenal [HPA] axis in humans: effects of GABA-, mineralocorticoid-, and GH-secretagogue-receptor modulation. Scientif World J 2006;6:1.
30. Iyengar S, Kim HS, Wood PL: Mu-, delta-, kappaand epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical [HPA] axis: subchronic tolerance studies of endogenous opioid peptides. Brain Res 1987;435:220.
31. Malcher-Lopes R, Franco A, Tasker JG: Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic antiinflammatory switch. Eur J Pharmacol 2008;583: 322.
32. Jezova D: Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications. Endocrine 2005;28:287.
33. Orth DN, Kovacs WJ: The adrenal cortex; in Wilson JD (ed): Williams Textbook of Endocrinology, ed 9. Philadelphia, Saunders,1998, pp 605-610.
34. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000;355:542.
35. Hopkins RL, Leinung MC: Exogenous Cushings syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 2005;34:371.
36. Krapf R: Development of Cushings syndrome after use of a herbal remedy. Lancet 2002;360:1884.
37. Agadi S: Iatrogenic Cushings syndrome: a different story. Lancet 2003;361:1059.
38. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M: Glucocorticoid like activity of megestrol: a summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997;157:1651.
39. Naef R, Schmid C, Hofer M, Minder S, Speich R, Boehler A: Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients. Respiration 2007;74:418.
40. Priftis KN, Papadimitriou A, Nicolaidou P, Chrousos GP: The hypothalamic-pituitary-adrenal axis in asthmatic children. Trends Endocrinol Metab 2008; 19:32.
41. Zöllner EW: Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids. 2. The risk as determined by gold standard adrenal function tests: a systematic review. Pediatr Allergy Immunol 2007;18:469.
42. Ambrogio AG, Pecori Giraldi F, Cavagnini F: Drugs and HPA axis. Pituitary 2008;11:219.
43. Garattini S, Mennini T: Critical notes on the specificity of drugs in the study of metabolism and functions of brain monoamines. Int Rev Neurobiol 1988;29:259.
44. Meltzer HY, Maes M: Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol Psychiatry 1994;35:316.
45. Bagdy G, Arato M: Gender-dependent dissociation between oxytocin but not ACTH, cortisol or TSH responses to m-chlorophenylpiperazine in healthy subjects. Psychopharmacology (Berl) 1998;136:342.
46. Laakmann G, Schüle C, Baghai T, Waldvogel E: Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999;24:769.
47. Monteleone P: Effects of trazodone on plasma cortisol in normal subjects: a study with drug plasma levels. Neuropsychopharmacology 1991;5:61.
48. Ansseau M, von Frenckell R, Franck G, Geenen V, Legros JJ: Dexamethasone suppression test and MMPI scales. Neuropsychobiology 1986;16:68.
49. Jenck F, Martin JR, Moreau JL: The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats. J Psychopharmacol 1999;13:166.
50. Pitchot W, Wauthy J, Hansenne M, Pinto E, Fuchs S, Reggers J, Legros JJ, Ansseau M: Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers. Psychopharmacology (Berl) 2002;164:27.
51. Lotrich FE, Pollock BG: Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatr Dis Treat 2005;1:17.
52. von Bardeleben U, Holsboer F, Gerken A, Benkert O: Mood elevating effect of fluoxetine in a diagnostically homogeneous inpatient population with major depressive disorder. Int Clin Psychopharmacol 1989;4(suppl 1):31.
53. Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME: 5-HT1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 1999;20:628.
54. Berlin I, Warot D, Legout V, Guillemant S, Schöllnhammer G, Puech AJ: Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther 1998;63:428.
55. Lanfumey L, Mongeau R, Cohen-Salmon C, Hamon M: Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci Biobehav Rev 2008;32:1174.
56. Yatham LN, Steiner M: Neuroendocrine probes of serotonergic function: a critical review. Life Sci 1993; 53:447.
57. St Germain RM, Yigit S, Wells L, Girotto JE, Salazar JC: Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent. AIDS Patient Care STDS 2007;21:373